1. 1) U.S. Food and Drug Administration, “FDA Drug Safety Communication: FDA recommends separating dosing of potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs.”: ‹https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-recommends-separating-dosing-potassium-lowering-drug-sodium›, cited 1 June, 2023.
2. 2) Harel Z., Harel S., Shah P. S., Wald R., Perl J., Bell C. M., Am. J. Med., 126, 264.e9–264.e24 (2013).
3. 3) Evans B. M., Jones N. C., Miline M. D., Yellowless H., Lancet, 262, 791–795 (1953).
4. 4) Kessler C., Ng J., Valdez K., Xie H., Geiger B., J. Hosp. Med., 6, 136–140 (2011).
5. 5) Interview form of Kayexalate® powder (sodium polystyrene sulfonate, SPS). ‹https://www.torii.co.jp/iyakuDB/data/if/if_kay.pdf›, cited 1 June, 2023.